Evaluaciones económicas

Published on 15 de marzo de 2022 | http://doi.org/10.5867/medwave.2022.02.002118

Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru

Back to article Table 6.

Cost-effectiveness analysis in adults and children with inhibitors, from Ministry of Health and Social Security Health Insurance, comparing current scheme with emicizumab prophylaxis.